Details for Patent: 8,853,404
✉ Email this page to a colleague
Title: | Muscarinic acetylcholine receptor antagonists |
Abstract: | Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. |
Inventor(s): | Laine; Dramane Ibrahim (King of Prussia, PA), Palovich; Michael R. (King of Prussia, PA), McCleland; Brent W. (King of Prussia, PA), Neipp; Christopher E. (King of Prussia, PA), Thomas; Sonia M. (King of Prussia, PA) |
Assignee: | Glaxo Group Limited (Brentford, Middlesex, GB) |
Filing Date: | Oct 14, 2013 |
Application Number: | 14/052,816 |
Claims: | 1. A compound of formula (I) ##STR00047## wherein: R1 is ##STR00048## R2 and R3 are independently selected from the group consisting of: ##STR00049## where F, G, H, K, and L are independently selected from the group consisting of hydrogen, halogen, --C 1-4 alkyl, halosubstituted --C 1-4 alkyl, hydroxyl substituted alkyl, and --C 1-4 alkoxy; l is an integer having a value of 1 or 2; n is an integer having a value of 1 to 4; M is O or CH.sub.2; V is O or CH.sub.2; X.sup.- is a pharmaceutically acceptable anion. 2. The compound according to claim 1 wherein X.sup.- is a pharmaceutically acceptable anion selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate, and p-toluenesulfonate. 3. The compound according to claim 1 wherein M is O. 4. The compound according to claim 3 wherein n is 2. 5. The compound according to claim 4 wherein l is 2. 6. The compound according to claim 1 wherein V is CH.sub.2. 7. The compound according to claim 1 wherein V is O. 8. The compound according to claim 1 wherein M is CH.sub.2. 9. The compound according to claim 1 wherein l is 1. 10. The compound according to claim 1 wherein l is 2. 11. The compound according to claim 2 wherein one of R2 and R3 is: ##STR00050## 12. The compound according to claim 2 wherein both R2 and R3 are independently selected from: ##STR00051## 13. The compound according to claim 2 wherein one of R2 and R3 is: ##STR00052## 14. The compound according to claim 2 wherein one of R2 and R3 is: ##STR00053## 15. The compound according to claim 1 which is: 4-[hydroxy(diphenyl)methyl]-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1-az- oniabicyclo[2.2.2]octane bromide. 16. A pharmaceutical composition comprising a compound according to claim 1, and a pharmaceutically acceptable carrier thereof. 17. A pharmaceutical composition comprising a compound according to claim 15, and a pharmaceutically acceptable carrier thereof. 18. A pharmaceutical composition according to claim 1 in a form suitable for administration by oral or nasal inhalation. 19. A pharmaceutical composition according to claim 18 wherein the form is suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler, or a metered dose inhaler. 20. A pharmaceutical composition according to claim 19 which is a dry powder composition. |